|Articles|December 8, 2021

Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone
Volume 27
Issue 20

eAppendix: ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

Author(s)Linda F. Fried, MD, MPH, Natalia Petruski-Ivleva, PhD, Kerstin Folkerts, MSc

Supplementary Appendix

Download PDF

Articles in this issue

over 4 years ago

Article

Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone - Participating Faculty

over 4 years ago

Article

ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

over 4 years ago

Article

Medical Costs for Managing Chronic Kidney Disease and Related Complications in Patients With Chronic Kidney Disease and Type 2 Diabetes

over 4 years ago

Article

FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

over 4 years ago

Article

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Unhealthy food | Image Credit: beats_ - stock.adobe.com

Dietary Risks Tied to Rising Global CKD Burden

ByBrooke McCormick

August 18th 2026

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Atacicept Shows Encouraging Safety Profile in IgA Nephropathy: Richard Lafayette, MD

ByBrooke McCormick,Richard Lafayette, MD, FACP

August 5th 2026

Richard Lafayette, MD | Image Credit: Stanford Medicine

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

ByBrooke McCormick,Richard Lafayette, MD, FACP

August 3rd 2026

Kidneys-natali_mis | Image credit: stock.adobe.com

Paricalcitol Tied to Lower Mortality Than Calcitriol in CKD

BySkylar Jeremias

July 31st 2026

eAppendix: ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

Articles in this issue

Related Content

Dietary Risks Tied to Rising Global CKD Burden

Predicting GLP-1 Discontinuation From Pharmacy Claims

Atacicept Shows Encouraging Safety Profile in IgA Nephropathy: Richard Lafayette, MD

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Paricalcitol Tied to Lower Mortality Than Calcitriol in CKD

Trending on AJMC

FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes

Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk

US Employer Health Care Costs Projected to Rise 9.5% in 2027

MRI Shows Hypothalamic Atrophy in Narcolepsy Type 1, Sparing Subregion

DOJ Abandons Olmstead Defense as Texas v Kennedy Advances